The U.S based company, Pfizer Inc. (NYSE: PFE) which is ranked #2 in sales, invested $5.8 bn EUR in 2006 into research and development. In 2007 the company made the major decision to invest in biotech drugs which are less susceptible to generic competition. It reorganized its R&D operations by hiring Martin Mackay as its new chief of global R&D and announced the launch of a biotherapeutic and bioinnovation center to focus on securing new technologies and discovering new medicines. In December Pfizer announced that it was closing its Ann Arbor research facility and laying off 2,100 employees due to the fact that Lipitor is nearing the end of its patent life.
During a recent update Pfizer announced that it has 47 Phase II drugs, 11 Phase III drugs and 14 biologics in its pipeline.
Drugs Pending Approval:
Lasofoxifene - Osteoporosis
Maraviroc - HIV in Treatment Experienced Patients
Dalbavancin - Skin and Skin Structure Infections
Phase III:
CP-945598 - Obesity
Apixaban - Venous Thromboembolism prevention, Atrial Fibrillation
Zithromax/Chloroquine - Malaria
CP-675206 - Melanoma
Axitinib - Thyroid Cancer/Pancreatic Cancer
Sutent - Breast Cancer, Colorectal Cancer, Lung Cancer
Maraviroc - HIV in Treatment Naïve Patients
Lyrica - Epilepsy Monotherapy, Generalized Anxiety Disorder (U.S.)
Geodon - Bipolar Relapse Prevention
[Source: FierceBiotech]
.jpg)
Comment Preview